The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT

NCT05596981 · clinicaltrials.gov ↗

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia With FLT3/ITD Mutation
Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Sorafenib

Sponsor

Nanfang Hospital, Southern Medical University